Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
Canada’s Medicago announced the successful production of a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 gene. The company is focused on developing a vaccine for COVID-19, the virus caused by SARS-CoV-2.
Repertoire Immune Medicines officially launched following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines. The new company is focused on tapping into the powers of the immune system to address numerous diseases.
While employees of Cambridge, Massachusetts-based Biogen who attended a management meeting in Boston tested positive for COVID-19, numerous biopharma organizations are cancelling or postponing activities that involve large groups of people.
The U.S. Food and Drug Administration is putting a halt to the sale of alleged treatments for COVID-19 due to concerns about the safety risks these products could have to the public.
Biogen instructed company staff to work from home following additional employees testing positive for the coronavirus. According to reports, 15 employees who attended a management meeting in Boston tested positive for the virus.
Three employees of Boston-based Biogen tested positive for the novel coronavirus.
A global coalition set up to fight epidemic diseases issued a call for $2 billion to support the development of a vaccine against the new coronavirus that is causing COVID-19 infections around the world.
As Seattle and outlying areas serve as the front lines of the coronavirus outbreak in the United States, with at least 10 deaths related to COVID-19 reported in the state of Washington, Fred Hutchinson Cancer Research Center implemented a mandatory remote work policy.
Japanese drug manufacturer Takeda Pharmaceutical indicated that the company is attempting to develop a drug based on the blood of patients who recovered from COVID-19.
